金沙官网金沙注册金沙平台

His areas of clinical expertise include chronic kidney disease, cardiovascular disease risk, acute renal failure and studying the relationship between renal disease and cardiovascular complications. Other areas of focus include arterial hypertension, specifically hypertension in chronic kidney disease, clinical pharmacology and toxicology, and medical education and technology. Dr. Guzman, an established research lead, has been invited to a variety of lectures and conferences to speak about his work. He has served on many scientific review, advisory and editorial review boards as a trusted expert. Dr. Guzman’s vast experience in the cardio-renal disease space continues to make him a valuable asset to AstraZeneca and to the chronic kidney disease franchise.


With chronic kidney disease affecting 更多 than 200 million people worldwide, I am proud that AstraZeneca is taking the lead and is fully committed to building a 文件夹 that will establish us as a scientific leader in the cardio-renal space.

Nicolas Jose Guzman, M.D. Director Physician, Nephrology Clinical Research

金沙平台

LATEST PROJECT

金沙app旧版

ASSOCIATE PROFESSOR

金沙app旧版

DIRECTOR OF ACUTE DIALYSIS AND RENAL SUPPORT 服务

金沙app旧版

DIRECTOR OF OUTPATIENT CLINICS

金沙app旧版

DIRECTOR OF DIABETES AND RENAL DISEASE CLINIC

金沙app旧版

DIRECTOR, MOLECULAR SIGNALING LABORATORY

金沙app旧版


Featured publications
金沙app旧版

Chronic Kidney Disease Outcomes金沙官网金沙注册金沙平台

Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS; CRIC Study Investigators: Chronic Renal Insufficiency Cohort (CRIC) Study: Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012 Dec; 7(12):1938-46

Wing MR, Yang W, Teal V, Navaneethan S, Tao K, Ojo A, Guzman NJ, Reilly M, Wolman M, Rosas SE, Cuevas M, Fischer M, Lustigova E, Master SR, Xie D, Appleby D, Joffe M, Kusek J, Feldman HI, Raj DS, Chronic Renal Insufficiency Cohort (CRIC) Study: Race modifies the association between adiposity and inflammation in patients with chronic kidney disease: finding from the chronic renal insufficiency cohort study. Obesity (Silver Spring). 2014 May; 22(5):1359-66

Wing MR, Devaney JM, Joffe MM, Xie D, Feldman HI, Dominic EA, Guzman NJ, Ramezani A, Susztak K, Herman JG, Cope L Harmon B, Kwabi-AddoB, Go AS, He J, Lash JP, Kusek JW, Raj DS, Chronic Renal Insufficiency Cohort (CRIC) Study: DNA Methylation Profile Associated with Rapid Decline in Kidney Function: Findings from the CRIC Study. Nephrol Dial Transplant. 2014 Apr; 29(4):864-72

Hypertension and Kidney Disease of Diabetes Mellitus. A Review 金沙官网金沙注册金沙平台

Guzman NJ: Hypertension and Kidney Disease of Diabetes Mellitus. A Review. J. Florida M. A. 1991; 78(11):751-753.

Acute Renal Failure金沙官网金沙注册金沙平台

Guzman NJ and Peterson JC: Acute Renal Failure. In: Tisher CC and Wilcox CS, eds. Nephrology. 3rd ed. Balti更多: Williams & Wilkins, 1995; 69-82.

 

Use of Drugs in Renal Failure金沙官网金沙注册金沙平台

Guzman NJ: Use of Drugs in Renal Failure. In: Tisher CC and Wilcox CS, eds. Nephrology. 3rd ed. Balti更多: Williams & Wilkins, 1995; 277-290.

Screening for Primary Hyperaldosteronism in CKD Patients with Resistant Hypertension: An Evaluation of Practice Patterns (Abstract Presentation)金沙官网金沙注册金沙平台

Screening for Primary Hyperaldosteronism in CKD Patients with Resistant Hypertension: An Evaluation of Practice Patterns - Antonio Ligon MD, Samir Patel MD and Nicolas Guzman MD - Mid-Atlantic Fellows Forum 2010, Baltimore, MD.

Drug Overdose and Poisoning金沙官网金沙注册金沙平台

Guzman NJ and Friedman PA : Drug Overdose and Poisoning. In: Parrillo JE, ed. Current Therapy in Critical Care Medicine, Philadelphia, Pennsylvania : B.C. Decker, 1987; 318-323.


金沙app旧版

金沙官网9304

金沙官网金沙注册金沙平台

金沙官网金沙注册金沙平台

金沙官网登录注册

金沙官网金沙注册金沙平台

金沙官网金沙注册金沙平台

金沙登录平台

金沙官网金沙注册金沙平台

金沙官网金沙注册金沙平台



金沙app旧版

and help us deliver life-changing medicines 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.